Multiple sclerosis

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors

Retrieved on: 
火曜日, 5月 7, 2024
Stanford University, University, FGFR, Disorder, Fibroblast growth factor receptor, Hospital, NDA, QED, Achondroplasia, Hematology, Bile duct, Drug, Research and development, MAA, Yale University, RET, Growth, Duke University, Biotechnology, Therapy, Faculty, Osteochondrodysplasia, Harvard Medical School, Multiple sclerosis, Biology, Drug development, Drug discovery, Liver cancer, Bristol Myers Squibb, Massachusetts General Hospital, Puma Biotechnology, Pharmaceutical industry

and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.

Key Points: 
  • and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D.
  • "Susan and Michael's impressive careers will provide TYRA with valuable guidance as we advance our potential next-generation precision candidates toward people in need.
  • In connection with these appointments, Dr. Chen, who has served as a director since June 2020, has resigned from the TYRA Board.
  • "On behalf of the Board, I want to thank Isan for his many contributions to TYRA.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
火曜日, 5月 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
火曜日, 5月 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on: 
木曜日, 5月 2, 2024
Nerve, Brain, Enzyme, University, Cell nucleus, Mouse, Tissue, H3K9me3, Organoid, Thought, H3K27ac, Doctor of Philosophy, Axon, Research, Remyelination, Disease, OLS, Cholesterol, Movement, Gene expression, Multiple sclerosis, Regeneration, Ageing, H3K27me3, Tetraplegia, Pharmaceutical industry

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points: 
  • When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
  • Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
  • In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
  • When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

Memorial Neuroscience Institute First in South Florida to Utilize Latest Aneurysm Treatment Technology

Retrieved on: 
月曜日, 4月 29, 2024
Leg, FDA, Brain, Aneurysm, Stroke, Bleeding, Permanent Damage, Safety, Neck, Survival, Interventional neuroradiology, Arm, Medtronic, Spine, Patient, Wrist, Headache, Physician, Memorial Hermann Health System, Epilepsy, Neoplasm, Multiple sclerosis, Diagnosis, Rehabilitation, Multimedia, Human, Mehta, Medical imaging

HOLLYWOOD, Fla., April 29, 2024 /PRNewswire-PRWeb/ -- As a veterinarian in Cuba, Xiomara Delgado was used to providing clinical expertise to patients and families. Now retired and living in Miami, the 77-year-old doctor was recently on the other side of a diagnosis, and it wasn't a good one.

Key Points: 
  • - Dr. Brijesh P. Mehta
    Delgado periodically suffered from very painful headaches that were severe enough to require a visit to Memorial.
  • Delgado was immediately referred to Dr. Brijesh P Mehta , medical director of Neurointerventional Surgery and the Comprehensive Stroke Program at Memorial Neuroscience Institute.
  • Mehta is one of approximately 20 physicians in the U.S. trained to use Medtronic's Pipeline Vantage device for treatment of brain aneurysms.
  • Memorial Neuroscience Institute offers advanced diagnoses, comprehensive treatment, compassionate care, and rehabilitation for complex neurological conditions.

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

Retrieved on: 
木曜日, 4月 25, 2024
Conditional sentence, Cancer, Fibroblast, Communication, Trial of the century, Research, Degenerative disc disease, CDMO, Form, DNA, Therapy, Risk, Patient, Psoriasis, Charles River Laboratories, Multiple sclerosis, Wound healing, Drug discovery, Letter, Pharmaceutical industry

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.

Key Points: 
  • HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.
  • To help advance FibroBiologics’ fibroblast-based therapies into the clinic, Charles River will conduct feasibility studies on FibroBiologics' cell manufacturing processes within its facility.
  • Additionally, contingent upon entering into a master services agreement, Charles River would serve as the contract development and manufacturing organization (CDMO) responsible for producing drug products for certain FibroBiologics’ clinical trials.
  • Combined with its legacy testing capabilities, Charles River offers a premier “concept-to-cure” advanced therapies solution.

Canadians Come Together to Make Positive Impact During Multiple Sclerosis Awareness Month This May

Retrieved on: 
水曜日, 4月 24, 2024
Volunteering, Social media, Hope, Multiple sclerosis research, Research, Friends, Disease, Family, Caregiver, Parliament, Diagnosis, Multiple sclerosis, DSM-IV codes, Government, Quality of life, Letter, Prevalence, Online shopping

TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- May is Multiple Sclerosis (MS) Awareness Month and MS Canada invites Canadians to join the MS community and navigate MS together.

Key Points: 
  • TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- May is Multiple Sclerosis (MS) Awareness Month and MS Canada invites Canadians to join the MS community and navigate MS together.
  • MS Awareness Month is an opportunity to raise awareness and funds to support the over 90,000 Canadians living with the neurological disease.
  • This May we ask Canadians to come together and raise awareness, celebrate the MS community, and have a meaningful impact across Canada.
  • For more information about MS Awareness Month, including how you can get involved, please visit mscanada.ca/msawarnessmonth.

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Retrieved on: 
水曜日, 4月 24, 2024
Ulcerative colitis, TNFR2, Vitiligo, TEL, Research, Development, IND, Exercise, Autoimmune disease, Patient, Multiple sclerosis, Immune system, Antibody, Biotechnology, Autoimmunity, SAN, Vaccine

The research collaboration was established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II (TNFR2), a novel, biologically-validated disease target implicated in a wide range of autoimmune diseases that has been difficult to drug with conventional medicines.

Key Points: 
  • The research collaboration was established to design and test agonistic antibodies targeting tumor necrosis factor receptor type II (TNFR2), a novel, biologically-validated disease target implicated in a wide range of autoimmune diseases that has been difficult to drug with conventional medicines.
  • Under the 2021 research agreement, Nektar has tested antibodies computationally designed by Biolojic Design to precisely agonize the TNFR2 receptor.
  • If the NKTR-0165 candidate proceeds through clinical development, Biolojic Design is entitled to development milestones and sales royalties.
  • Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: “The unique agonist antibodies directed at TNFR2 are yet another demonstration of the power of Biolojic’s AI platform for antibody design.

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Retrieved on: 
水曜日, 4月 24, 2024
Doctor of Philosophy, HSDT, Pain, FAAN, Stroke, Risk, Falling, Brain, Rehabilitation, Gait, Innovation, Pons, Survivor, Shepherd Center, Patient, Spinal cord, Helios, Multiple sclerosis, MBA, Management of multiple sclerosis, Pharmaceutical industry

NEWTOWN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of its clinical development program for the broadening of the labeling of its marketed PoNS device to include patients recovering from stroke with the participation of Shepherd Center, under the direction of Michael Yochelson, M.D., MBA, FAAN, FAAPMR, Chief Medical Officer. Participating to the Company-sponsored single-arm study, Shepherd Center joins Brooks Rehabilitation as a third clinical site to the overall registrational program. As one of the nation’s top neurorehabilitation hospitals, Shepherd Center is known for its innovation, patient outcomes exceeding the national average, and expertise in providing world-class clinical care for people experiencing the most complex conditions, including stroke, spinal cord and brain injuries, multi-trauma, traumatic amputations, multiple sclerosis, and pain.

Key Points: 
  • Participating to the Company-sponsored single-arm study, Shepherd Center joins Brooks Rehabilitation as a third clinical site to the overall registrational program.
  • “Shepherd Center has been a valuable partner to Helius for almost two years.
  • We are delighted Dr. Yochelson has agreed to contribute to the implementation of our stroke registrational program and undertake the study at Shepherd Center,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer.
  • “Shepherd Center’s earlier involvement with the MS program is a testament to the strength of our clinical program.

Regeneration Biomedical Doses First Patient in a First-in-Human Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brain of Patients with Alzheimer’s Disease

Retrieved on: 
火曜日, 4月 23, 2024
FDA, Brain, Inflammation, Cell, Safety, Hope, Research, Collection, IRB, B cell, Lateral ventricles, Stem cell, Patent, Patient, Regeneration, Caregiver, BBB, Scalp, Multiple sclerosis, Adipose tissue, Neuron, Traumatic brain injury, Biomarker, Clinical trial, RBI, Pharmaceutical industry

Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.

Key Points: 
  • Stem cells have represented a novel approach to treatment, but evidence of efficacy has been elusive because systemically administered cells are unable to bypass the blood brain barrier (BBB) and enter the brain.
  • Our RB-ADSC product candidate is designed to overcome the BBB by delivering potentially efficacious stem cells directly to the brain.
  • In vivo studies demonstrated that stem cells injected in this fashion do locate into the ventricles and parenchyma.
  • Research in two animal models has demonstrated that stem cells infused into the ventricular system distribute themselves into brain parenchyma.